Literature DB >> 28095357

Establishment of a fluorescence-based method to evaluate endocytosis of desialylated glycoproteins in vitro.

Cheng Luo1, Song Chen1, Na Xu1, Wen Bo Sai1, Wei Zhao2, Ying Chun Li2, Xiao Jing Hu2, Hong Tian2, Xiang Dong Gao3, Wen Bing Yao4.   

Abstract

Insufficient sialylation can result in rapid clearance of therapeutic glycoproteins by intracellular degradation, which is mainly mediated by asialoglycoprotein receptors (ASGPRs) on hepatic cells. In contrast, for glycoproteins, a long half-life is often related to high level of terminal sialic acid. These could be extremely important for insufficient sialylated biomedicines in clinic, and development of therapeutic glycoproteins in laboratory. However, how the desialylated glycoproteins are removed and how to evaluate the ASGPRs mediated endocytosis in vitro needs further investigate. Herein we described an integrative characterization of ASGPRs in vitro to elucidate its endocytosis properties. The endocytosis was determined by a fluorescence-based quantization method. The results showed that the ASGPRs could bind to poorly sialylated glycoproteins including asialofetuin and low sialylated recombinant Factor VIIa with a relatively higher ASGPRs binding affinity, and induce a more rapid endocytosis in vitro. Moreover, the mechanism under the internalization of ASGPRs was also investigated, which was found to depend on clathrin and caveolin. Utilizing the relative fluorescence quantification can be suitable for measurement of insufficient sialylated glycoprotein endocytosis and quality control of therapeutic glycoproteins, which could be useful for the understanding of the development of therapeutic glycoproteins.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Asialoglycoprotein receptors; Endocytosis; Fluorescence quantification

Mesh:

Substances:

Year:  2017        PMID: 28095357     DOI: 10.1016/j.biopha.2016.12.085

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  1 in total

1.  Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties.

Authors:  Cheng Luo; Song Chen; Na Xu; Chi Wang; Wen Bo Sai; Wei Zhao; Ying Chun Li; Xiao Jing Hu; Hong Tian; Xiang Dong Gao; Wen Bing Yao
Journal:  Sci Rep       Date:  2017-04-11       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.